Comparison of inhaled colistin versus intravenous colistin for gram-negative hospital-acquired pneumonia: a prospective randomized controlled trial
Abstract
Background:
Hospital-acquired pneumonia (HAP) is a significant morbidity, mortality and increasing healthcare cost associated with gram-negative pathogens. Conventional intravenous (IV), last-resort colistin is limited by its systemic toxicity and lack of lung tissue penetration. In contrast, inhaled colistin provides targeted pulmonary delivery to limit exposure beyond the opposite lung, hence improving therapeutic efficacy over the systemic effects.
Methods:
As a prospective, randomized, controlled trial, adult patients in the age group of 18 to 65 years suffering from culture-confirmed gram-negative HAP were enrolled at JPMC, Karachi, over January 2025 to June 2025.For 14 days, there were 80 patients randomized to two equal groups (n = 80 each) who were given either IV or inhaled colistin sodium (2 million international units three times daily by jet nebulization). Clinical cure was defined as the complete resolution of pneumonia signs and symptoms with radiographic improvement and no additional antibiotics. Microbiological eradication, 28 days, all cause mortality and incidence of adverse events, especially nephrotoxicity, were secondary endpoints that were studied. The sample size was determined to have 80% power and an alpha value of 0.05, assuming the inhaled clinical cure rate to be 59% and the IV clinical cure rate to be 37%. Analyses of the data were carried out in SPSS v26 with Chi square tests for categorical variables and t tests or Mann-Whitney U tests for the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 80 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.